Jaguar8 commented on a stock · Oct 28, 2024 19:25

NEWS

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Precision BioSciences (Nasdaq: DTIL) announced a virtual Hepatitis B Investor Event scheduled for November 15, 2024. The event will feature Key Opinion Leaders and members of Precision's Hepatitis Scientific Advisory Board discussing the current hepatitis B treatment landscape, which only achieves 1-3% functional cure rates. The presentation will focus on PBGENE-HBV, their gene editing approach targeting cccDNA elimination and HBV DNA inactivation. The company will present final preclinical safety data and phase 1 clinical trial plans following Clinical Trial Application approval in Moldova.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more